This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...
Regenxbio has received a "Strong Buy" rating from analysts following a significant FDA course reversal regarding its drug NAVSUNLI. This positive development is further bolstered by the potential for an Accelerated Approval (AA) Duchenne Muscular Dystrophy (DMD) filing,…
Market Samachar is a news aggregator. This article was originally published by seekingalpha.com. Tap the button above to read the full story on their site.